$15.54 -0.33 (-2.08%)

Integra LifeSciences Holdings (IART)

Integra LifeSciences Holdings is a global medical device company specializing in surgical instruments, neuro and spinal devices, and wound care products. Founded in 1989, it focuses on developing innovative solutions for healthcare providers to improve patient outcomes across neurosurgery, orthopedics, and general surgery.

🚫 Integra LifeSciences Holdings does not pay dividends

Company News

Craniomaxillofacial Devices Market Industry Trends, Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2034
GlobeNewswire Inc. • Researchandmarkets.Com • September 25, 2025

The global craniomaxillofacial devices market is projected to grow from $1.8 billion in 2024 to $3.9 billion by 2034, driven by increased facial injuries, technological advancements, and minimally invasive surgical techniques.

Chronic Wound Care Market to Expand at a Modest 4.17% CAGR through 2031 | SkyQuest Technology
Benzinga • Globe Newswire • November 26, 2024

The chronic wound care market is expected to grow at a CAGR of 4.17% from 2024 to 2031, driven by the high prevalence of chronic diseases and advancements in wound care technologies. The market is segmented by product, application, end-user, and region, with North America leading due to its developed healthcare infrastructure.

Why Integra Lifesciences Stock Is Sinking Today
The Motley Fool • Keith Speights • July 29, 2024

Integra Lifesciences (IART) shares fell 15.5% after the company reported Q2 results that topped estimates but provided disappointing full-year guidance, citing operational challenges and investments in compliance improvements.

Why Is Integra (IART) Up 26% Since Last Earnings Report?
Zacks Investment Research • Zacks Equity Research • June 5, 2024

Integra (IART) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

‘Earnings are better, valuations are cheaper.’ Here are 18 small-cap stock ideas from Jefferies
MarketWatch • MarketWatch • July 14, 2021

Investors have started to sour on the vaccine and postelection bets and small-cap stocks are taking it on the chin. Our call of the day says consider these higher quality, cheap names.